|
JSB462 Clinical Trials
2 actively recruiting trials across 1 location
No change since May 2026
Also known as: luxdegalutamide
Pipeline
Phase 1: 1Phase 2: 1
Top Sponsors
- Novartis Pharmaceuticals2
Indications
- Cancer2
- Metastatic Prostate Cancer (mCRPC)1
- Metastatic Hormone-sensitive Prostate Cancer1
Other1 trial
La Jolla, California1 trial
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
University of California San Diego - Moores Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.